You are here: Industry Insights > AstraZeneca

News List

AstraZeneca transfers rights for Eklira and Duaklir to Covis Pharma EuropeanPharmaceuticalReview
November 05, 2021
AstraZeneca has agreed to transfer its global rights to Eklira (aclidinium bromide), known as Tudorza in the US, and Duaklir (aclidinium bromide/formoterol) to Covis Pharma.
Integral Molecular, AstraZeneca Enter Oncology Antibody Alliance ContractPharma
November 04, 2021
Integral Molecular, a developer of antibodies against membrane proteins, entered an exclusive worldwide antibody license agreement with AstraZeneca to develop therapeutics for multiple cancers.
AstraZeneca and Oncoshot establish strategic partnership to better streamline recruitment process for cancer clinical trials prnasia
September 28, 2021
Singapore's cancer population may benefit from improved access to cutting-edge clinical trials through InSite Feasibility - Oncoshot's new digital platform that facilitates...
Korea’s messaging around AstraZeneca vaccine prompts confusion firstwordpharma
August 19, 2021
AstraZeneca’s COVID-19 vaccine this week became available in South Korea to people in their 30s and 40s, even though the official cutoff age hasn’t changed, reported The Korea Herald.
UK-donated COVID-19 vaccine doses reach African countries firstwordpharma
August 16, 2021
The first AstraZeneca doses donated to COVAX by the United Kingdom (UK) will soon arrive in Angola, Egypt, Ethiopia, Ghana, Kenya, Malawi, Nigeria, Senegal and Uganda, with Zambia and DRC set to be the first to receive these UK-donated vaccines.
US rejects AZ and FibroGen’s anaemia drug roxadustat pharmatimes
August 13, 2021
The US Food and Drug Administration (US) has handed AstraZeneca a complete response letter (CRL) regarding its anaemia drug roxadustat.
Age restrictions on AstraZeneca shot have ended reports of rare clots -UK scientists firstwordpharma
August 12, 2021
No new cases of rare and severe blood clots following vaccination with AstraZeneca's COVID-19 shot have been reported in the UK in recent weeks after a decision to restrict its use in people under the age of 40, scientists said Wednesday.
AstraZeneca India’s Q1 net profit declines 45 per cent expresspharma
August 11, 2021
Revenue from operations stood at Rs 175.40 crores for the quarter under consideration. It was Rs 193.57 crores for the same period a year ago.
Enhertu improves progression-free survival in breast cancer trial pharmatimes
August 09, 2021
Positive topline results from a Phase III trial for Daiichi Sankyo and AstraZeneca’s breast cancer drug Enhertu have shown that the HER2-directed antibody drug conjugate (ADC) ADC demonstrated superiority over trastuzumab emtansine (T-DM1).
AZ’s Forxiga gains EC, MHRA approvals for chronic kidney disease pharmatimes
August 09, 2021
AstraZeneca’s Forxiga (dapagliflozin), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, has been approved by the European Commission for the treatment of chronic kidney disease (CKD) in the European Union (EU).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page